The present invention describes IL-1&bgr； binding proteins, including chimeric, CDR-grafted, and humanized antibodies that bind IL-1&bgr；. Binding proteins of the invention have high affinity for IL-1&bgr； and neutralize IL-1&bgr； activity. A binding protein of the invention can be a full-length antibody or an IL-1&bgr；-binding portion thereof. Methods of making and methods of using the binding proteins of the invention are also described. The IL-1&bgr； binding proteins of the invention are useful for detecting IL-1&bgr； and for inhibiting IL-1&bgr； activity, including in a human subject suffering from a disease or disorder in which IL-1&bgr； activity is detrimental.
